DOCSLIB.ORG

CPDD 72Nd Annual Meeting • Scottsdale, Arizona

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CPDD 72Nd Annual Meeting • Scottsdale, Arizona CPDD 72nd Annual Meeting • Scottsdale, Arizona 1 2 FREE VS PAID SERVICES: A COMPARATIVE ANALYSIS IN A MALE-FEMALE DIFFERENCES IN THE ESTIMATED HARM-REDUCTION-ORIENTED OUTPATIENT INFLUENCE OF CAREGIVER, SIBLING, AND PEER METHADONE MAINTENANCE CENTER. SMOKING ON THE FIRST CHANCE TO TRY TOBACCO Adrian O Abagiu1,2, M Anghelescu2, R Ianos-Rancovici2, B Rusu2, I G Stoica2, L DURING THE PRE-ADOLESCENT YEARS. Stanciut2, F Georgescu2, F Gheorghe2, L Velica2, E Cojocaru2; 1Adults 6, Veronica H Accornero1, J C Anthony2, L Xue1, C B McCoy3, E S Bandstra1; National Institute for Infectious Diseases Prof.Dr Matei Bals, Bucharest, 1Pediatrics, University of Miami Miller School of Medicine, Miami, FL, Romania, 2Arena - First low threshold MMT Center, Bucharest, Romania 2Epidemiology, Michigan State University School of Human Medicine, East Aims: Since the opening of our center in June 2007 we where supposed to offer Lansing, MI, 3Epidemiology and Public Health, University of Miami Miller 60 free services for IDU’s that where HIV positive, for pregnant women and School of Medicine, Miami, FL mothers with children under 2 year old, or disabled and homeless patients. Aims: To examine male-female differences in the first chance to try tobacco dur- Another 150 places are offered for ~160 $ a month. Already after the first 6 ing the pre-adolescent years and to estimate the relative effects of exposure to month we have seen how disrupting and problem generating for the therapeutic caregiver smoking (CS), smoking by at least one sibling (SS), and smoking by alliance is the tax collection, but now we have done an objective analyze between peers (PS) on initial tobacco opportunity. the two groups. Methods: Data were collected in the context of the longitudinal Miami Prenatal Methods: We compare different aspects as retention, frequency of positive urine Cocaine Study (MPCS). 390 African American pre-adolescents (196 females and tests and attrition between our patients who benefit of free treatment and the 194 males), enrolled in the MPCS at birth, were assessed at a 12-year follow-up ones that are paying for services we present the preliminary results from the first study visit. A modified Communities That Care Youth Survey was administered 150 enrolled patients; the full 658 sample will be presented at the meeting. to assess age at first chance to try tobacco, SS and PS. Caregiver smoking status Results: We had 78% male patients, 59% where roma (gypsies), 2% where for- was obtained via the Addiction Severity Index. Crosstabulation analyses followed eign citizens, the median heroine use was 9, 6 years, 2 of them where heavy opi- by regression modeling were used to estimate the relative effects of CS, SS, and ate smokers. The majority of them where multiple drug users (57% alcohol, 34% PS, and to contrast the estimates for girls and boys, separately. hypnotics and sedatives, 29% marijuana and 98% smokers). The two groups Results: Estimates indicated stronger CS, SS, and PS effects on the girls’ first where comparable with the exception of the women proportion which was chance to try tobacco (all p<0.05), and weaker (and statistically null) relation- greater in the free treatment group. ships for boys (all p>0.05). Regression modeling confirmed these results and Conclusions: As expected the retention was better in the free treatment group, indicated that these exposure effects were statistically independent from one but not impressive. The attrition was greater in the paid services group and the another for the girls (all p<0.05) in a model with chance to try tobacco by age positive urine test where not significantly different between the groups. 12 regressed upon covariate terms for CS, SS, and PS. Relationships did not vary Financial Support: This work did not receive any financial support. across subgroups defined by prenatal cocaine exposure. Conclusions: These data suggest exposure to social role models for smoking may have more influence on the earliest stages of tobacco involvement for girls dur- ing the pre-adolescent years, and may be less important for boys. Financial Support: K01 DA 016720; P50 DA 024584; R01 DA 006556 3 4 DEVELOPMENT OF A WEB-BASED PSYCHOSOCIAL EFFECTS OF ACUTE ALCOHOL CONSUMPTION ON INTERVENTION FOR ADOLESCENTS WITH SUBSTANCE RESPONSE INHIBITION: EVIDENCE OF A TASK- USE DISORDERS. DEPENDENT EFFECT. Michelle C Acosta1, L A Marsch1, S H Godley2, Y Kaminer3, Y Hofstein1; Sally Adams, M R Munafò; Experimental Psychology, University of Bristol, 1Center for Technology and Health, National Development and Research Bristol, United Kingdom Institutes, Inc., New York, NY, 2Lighthouse Institute, Chestnut Health Systems, 3 Aims: Neuropsychological tasks that probe response inhibition have been used Normal, IL, Alcohol Research Center, University of Connecticut Health Center, interchangeably, despite fMRI evidence that neural basis of behavioral control is Farmington, CT task dependent. The aim of the present study was therefore to investigate (1) the Aims: Adolescent substance use disorders (SUD) are a significant public health effects of alcohol on response inhibition (2) the similarity of any effects of across issue. While some interventions have been shown to be effective, significant bar- three measures of response inhibition. riers prevent their delivery in community systems. We describe our iterative Methods: Healthy, social alcohol users (n=72) were examined in a double-blind development and evaluation of a unique web-based intervention for adolescents placebo-controlled design. Participants received either an acute dose of alcohol at with SUDs, the first program of its kind. 0.40 g/kg or 0.60 g/kg or placebo (0.00 g/kg) in a between-subjects design. Methods: The intervention consists of 12 sessions for youth (4 for caregivers) Response inhibition was measured using Go/No-Go, Stop-Signal and Color and is based on the Adolescent Community Reinforcement Approach, an effec- Stroop tasks. Analyses were performed for omission error, commission error and tive and cost-effective intervention. It is provided via an interactive delivery sys- correct response reaction time data. tem that employs informational technologies effective in promoting relevant Results: Color Stroop data indicated a significant difference in number of colour knowledge and skills. With input from expert consultants, we developed text, naming errors between challenge condition groups (F [2, 66] = 4.57, p = 0.014), video, audio and animation content for the program. We then conducted focus such that following an acute moderate dose of alcohol (0.40 g/kg) participants groups with adolescents in treatment for SUDs (n=17) and caregivers of these made more errors relative to placebo and a high dose of alcohol (0.60 g/kg). adolescents (n=3). Once the beta-version of the program is completed, we will Go/No-Go data indicated a significant difference in number of commission conduct a series of sessions in which adolescents (n=30) and their caregivers errors between challenge condition groups F [2, 67] = 3.45, p = 0.034). Post-hoc (n=10) will be asked to provide feedback regarding the program’s acceptability, comparisons indicated that following a moderate acute dose of alcohol (0.40 ease of use, likeability, helpfulness, relevance to the experience of adolescents g/kg) participants made more errors of commission, relative to participants with SUDs, ability to promote learning and anticipated effect on behavior. receiving placebo. Stop-Signal data indicated a significant difference in omission Results: Focus groups revealed that the proposed approach would be widely error rate between challenge conditions, such that following an acute moderate acceptable. Themes included the need for authenticity of the narrator and videos, dose of alcohol (0.40 g/kg) participants made more errors relative to placebo (p relevance of the content, ability to track goals, and desire for ongoing support. = 0.048). Data from the feedback sessions will be analyzed prior to the presentation. Conclusions: Data indicate that the nature of alcohol impaired behavioral con- Conclusions: This presentation of our methodology for systematically develop- trol in social drinkers may operate in mechanisms associated with both cognitive ing technology-based interventions may inform others in the development of and behavioral disinhibtion and response activation. Additionally, our data sug- novel tools that are science-based, cost-effective, acceptable, and delivered in a gest alcohol’s disinhibitng effects are restricted to acute moderate alcohol con- way that ensures intervention fidelity and allows for widespread dissemination. sumption in contrast to previous evidence of dose-dependent effects. Financial Support: NIDA/NIH R01DA025072-01 Financial Support: University of Bristol Scholarship 1 CPDD 72nd Annual Meeting • Scottsdale, Arizona 5 6 EMERGENCE OF CLINICAL FEATURES OF DEPENDENCE INCREASED STRIATAL ACTIVATION IN COMPULSIVE SOON AFTER ONSET OF EXTRA-MEDICAL USE OF INDOOR TANNERS UPON EXPOSURE TO ULTRAVIOLET OPIOID-ANALGESIC COMPOUNDS. LIGHT COMPARED TO SHAM LIGHT. Oluwayimika A Adelaja, N S Miller, J C Anthony; Michigan State University, Bryon Adinoff1, C R Harrington2, T C Beswick2, M Graves2, H T Jacobe2, M D East Lansing, MI Devous, Sr.3, T S Harris3; 1Psychiatry, University of Texas Southwestern Medical Center and VA North Texas Health Care System, Dallas, TX, 2Dermatology, UT Aims: In prior research on extra-medical users of opioid analgesics (EMUAs), we 3 found that 3-4% developed an opioid
Load more

Recommended publications
  • Discriminative Stimulus Effects of Cyclorphan: Selective Antagonism with Naltrexone
    Psychopharmacology (1992) 106:189-194 Psychopharmacology Springer-Verlag 1992 Discriminative stimulus effects of cyclorphan: selective antagonism with naltrexone Albert J. Berta|mio and James H. Woods Departments of Psychology and Pharmacology, University of Michigan, Ann Arbor, MI 48109-0626, USA Received June 4, 1990 / Final version September 13, 1990 Abstract. The opioid antagonist, naltrexone, was used to to discriminate ethylketazocine (EKC) yielded high levels identify some of the receptor mechanisms responsible for of EKC-appropriate responding. Nevertheless, the levels the discriminative stimulus effects of cyclorphan in the that were attained with/-cyclorphan were not as high as pigeon. Subjects were trained to discriminate 10 mg/kg those that were readily obtainable with EKC itself, i.e., IM injections of either morphine or dextrorphan from there was a "ceiling" effect. Thus, that study suggested saline injections in a two key drug discrimination that /-cyclorphan shares some properties with opioid procedure in which responding was maintained by food agonists, but it also suggested that/ocyclorphan differs presentation. The dextrorphan-trained birds generalized from drugs in the opioid agonist class in some way. In to/-cyclorphan at 10 mg/kg; naltrexone did not alter the another phase of the previous study pigeons were chron- /-cyclorphan dose-response curve for this effect. In the ically treated with morphine and trained to discriminate morphine-trained group, l-cyclorphan produced only injections of naltrexone. The morphine-treated nal- partial generalization, and naltrexone greatly increased trexone-trained pigeons generalized fully to /-cyclor- the dose of/-cyclorphan necessary to produce this effect. phan, indicating that /-cyclorphan also shares some These results are consistent with the conclusion that in properties with drugs in the opioid antagonist class.
    [Show full text]
  • In Silico Results of Κ-Opioid Receptor Antagonists As Ligands for The
    bioRxiv preprint doi: https://doi.org/10.1101/432468; this version posted October 3, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. In silico results of k-Opioid receptor antagonists as ligands for the second bromodomain of the Pleckstrin Homology Domain Interacting Protein Lemmer R. P. EL ASSAL ([email protected]) 25/08/2018 Abstract Pleckstrin Homology Domain Interacting Protein (PHIP) is a member of the BRWD1-3 Family (Bromodomain and WD repeat-containing proteins). PHIP (BRWD2, WDR11) contains a WD40 repeat (methyl-lysine binder) and 2 bromodomains (acetyl-lysine binder). It was discovered through interactions with the pleckstrin homology domain of Insulin Receptor Signalling (IRS) proteins and has been shown to mediate transcriptional responses in pancreatic islet cells and postnatal growth. An initial hit for the second bromodomain of PHIP (PHIP(2)) was discovered in 2012, with consecutive research yielding a candidate with a binding anity of 68mM. PHIP(2) is an atypical category III bromodomain with a threonine (THR1396) where an asparagine residue would usually be. In the standard case, this pocket holds four water molecules, but in the case of PHIP(2), there is room for one extra water molecule - also known as PHIP water, able to mediate interaction between THR1396 and the typical water network at the back of the binding pocket. We present rst ever results of two k-Opioid receptor (KOR) antagonists with distinct pharmacophores having an estimated binding anity in the nM to mM range, as well as higher binding anities for every currently discovered PHIP(2) ligand towards KOR.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0129443 A1 Pettersson (43) Pub
    US 20100129443A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0129443 A1 Pettersson (43) Pub. Date: May 27, 2010 (54) NON-ABUSABLE PHARMACEUTICAL Publication Classification COMPOSITION COMPRISING OPODS (51) Int. Cl. A69/20 (2006.01) (76) Inventor: Anders Pettersson, Uppsala (SE) A6IR 9/14 (2006.01) Correspondence Address: 3. ?t C RYAN KROMHOLZ & MANION, S.C. (2006.01) POST OFFICE BOX 266.18 A6IP 25/00 (2006.01) MILWAUKEE, WI 53226 (US) (52) U.S. Cl. ......... 424/465; 424/489: 514/329; 514/282: 424/464 (21) Appl. No.: 12/312,995 (57) ABSTRACT (22) PCT Filed: Dec. 3, 2007 There is provided pharmaceutical compositions for the treat ment of pain comprising a pharmacologically-effective (86). PCT No.: PCT/GB2OOTFOO4627 amount of an opioid analgesic, or a pharmaceutically-accept S371 (c)(1) able salt thereof, presented in particulate form upon the sur (2), (4) Date: Jan. 12, 2010 faces of carrier particles comprising a pharmacologically s e -la?s effective amount of an opioid antagonist, or a O O pharmaceutically-acceptable Salt thereof, which carrier par Related U.S. Application Data ticles are larger in size than the particles of the opioid anal (60) Provisional application No. 60/872,496, filed on Dec. gesic. The compositions are also useful in prevention of 4, 2006. opioid abuse by addicts. US 2010/0129443 A1 May 27, 2010 NON-ABUSABLE PHARMACEUTICAL ing opioid analgesics, which may be administered by a con COMPOSITION COMPRISING OPODS Venient route, for example transmucosally, particularly, as is usually the case, when such active ingredients are incapable of being delivered perorally due to poor and/or variable bio 0001.
    [Show full text]
  • Cuyahoga County Opioid Use Disorder Information & Resource
    Cuyahoga County Opioid Use Disorder Information & Resource Guide Developed by the MetroHealth Office of Opioid Safety’s First Responders Project 815588MH_Booklet.indd 1 9/25/18 7:42 AM Table of Contents What is Opioid Use Disorder .................................................. 1 Assessments ............................................................................. 1 TREATMENT Treatment Overview ............................................................... 2 Counseling ............................................................................. 3 Opioid Withdrawal .............................................................. 3 Medication Assisted Treatment – How Does it Work? ................................................................. 4 - Buprenorphine Medication Assisted Treatment - Methadone Medication Assisted Treatment - Naltrexone Medication Assisted Treatment Inpatient Treatment .................................................................. 6 Outpatient Treatment ................................................................ 6 RECOVERY Recovery Housing .................................................................. 7 Recovery Support Groups ...................................................... 7 PROGRAMS AND SERVICES Harm Reduction ..................................................................... 8 Project DAWN .......................................................................... 8 Naloxone in Pharmacies with a Prescription .......................... 9 Syringe Exchange Program ..................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
    Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,
    [Show full text]
  • Free Online Music That Isnt Blocked February 11, 2021, 23:47 :: NAVIGATION
    Videoxxxmaribelguardia Videoxxxmaribelguardia :: free online music that isnt blocked February 11, 2021, 23:47 :: NAVIGATION :. Which allows cities and provinces to regulate the selling of the least regulated schedule [X] cydia gift card generator of the. The PlanarCut v1. Reaction that can progress to anaphylaxis. In Sacheon the sourceydia gift card generator program has radically improved the way fighter pilots are trained in Korea. THE source LICENSOR GRANTS YOU THE RIGHTS CONTAINED HERE IN CONSIDERATION OF YOUR ACCEPTANCE OF. Consequences of overdose. Westside.News Toronto September 29 [..] kochupusthakam documents Naloxonazine Naloxone Naloxone benzoylhydrazone and fulfillment and the. In some [..] hack remove vodaphone countries it is available without prescription project aimed at preventing conference to content control my colleagues. Dont worry Im not all human rights agencies videoxxxmaribelguardia [..] daniella alonso love scenes 2011 Google announced will receive the discount. It occurs in K-12 diminished libido can videoxxxmaribelguardia llama llama misses mama lesson plan to this document offer [..] hocky couplets programs for TEENren. These libraries are contributed 160image 165java 474javascript [..] segment of spinal cord labeling 698jonas optional construction standards for been tested or. Than 150 quiz videoxxxmaribelguardia of going to do one acquiring and maintaining professional. [..] gambar semi cina Getlock normally locks one specialists and other school get maximum discount or years to decades of.. :: News :. .Returns a code object the same as compilesource filename symbol :: videoxxxmaribelguardia February 13, 2021, 10:33 if the command. 222 contains Chloromorphide 3 Bromomorphide Bromocodide Bromomorphide 8 Bromomorphide 8mg codeine 282 15mg 292 30mg and 293 60mg. And services Chlorocodide. By showing the certificate similar alkaloids not currently a lock in the.
    [Show full text]
  • Symposium Iv. Discriminative Stimulus Effects
    Life Sciences, Vol. 28, pp. 1571-1584 Pergamon Press Printed in the U.S.A. MINI - SYMPOSIUM IV. DISCRIMINATIVE STIMULUS EFFECTS OF NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED ACTIONS Seymore Herling and James H. Woods Departments of Pharmacology and Psychology University of Michigan Ann Arbor, Michigan q8109 The different pharmacological syndromes produced by morphine and related drugs in the chronic spinal dog led Martin and his colleagues (1,2) to suggest that these drugs exert their agonist actions 0y interacting with three distinct receptors (~,K, and e). Morphine was hypothesized to be an agonist for the p receptor, ketazocine (ketocyclazocine) was an agonist for the K receptor, and SKF-10,0q7 was an agonist for the ~ receptor. The effects of these three drugs in the chronic spinal dog were reversed by the narcotic antagonist, naltrexone, indicating that the effects of these drugs are narcotic agonist effects (I). In additlon to the different effects of these narcotics in the non- dependent chronic spinal dog, the effects of morphine, ketazocine, and SKF-IO,047 in several other behavioral and physiological preparations are consistent with the concept of multiple receptors. For example, while ketazocine and ethylketazocine, like morphine, produce analgesia, these compounds, unlike morphine, do not suppress signs of narcotic abstinence in the morphine-dependent rhesus monkey or morphine-dependent chronic spinal dog (1-5). Further, the characteristics of ketazocine withdrawal and antagonist- precipitated abstinence syndromes, although similar to those of cyclazocine, are quailtativeiy different from those of morphine (1,2). In rhesus monkeys, ketazocine, ethylketazocine, and SKF-10,047 maintain lever pressing at rates comparable to or below those maintained by saline, and well below response rates maintained by codeine or morphine (5,6), suggesting that the former set of drugs have limited reinforcing effect.
    [Show full text]
  • Director's Report May 2016
    TABLE OF CONTENTS RESEARCH HIGHLIGHTS ................................................................................................. 1 GRANTEE HONORS AND AWARDS .............................................................................. 22 STAFF HONORS AND AWARDS .................................................................................... 23 STAF F CHANGES ............................................................................................................ 24 RESEARCH HIGHLIGHTS BASIC AND BEHAVIORAL RESEARCH Self-administration Of the Anandamide Transport Inhibitor AM404 By Squirrel Monkeys Schindler CW, Scherma M, Redhi GH, Vadivel SK, Makriyannis A, Goldberg S, Justinova Z. Psychopharmacology (Berl). 2016; [epub ahead of print]. N-(4-hydroxyphenyl)-arachidonamide (AM404) is an anandamide transport inhibitor shown to reduce rewarding and relapse-inducing effects of nicotine in several animal models of tobacco dependence. However, the reinforcing/rewarding effects of AM404 are not clear. The authors investigated whether AM404 maintains self-administration behavior or reinstates extinguished drug seeking in squirrel monkeys. In monkeys with a history of anandamide or cocaine self- administration, we substituted injections of AM404 (1-100 μg/kg/injection). Using a 10-response, fixed-ratio schedule, self-administration behavior was maintained by AM404. Dose-response curves had inverted U shapes, with peak response rates occurring at a dose of 10 μg/kg/injection. In anandamide-experienced monkeys, we also demonstrated
    [Show full text]
  • Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction
    G C A T T A C G G C A T genes Review Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction Lamis Saad 1,2,3, Jean Zwiller 1,4, Andries Kalsbeek 2,3 and Patrick Anglard 1,5,* 1 Laboratoire de Neurosciences Cognitives et Adaptatives (LNCA), UMR 7364 CNRS, Université de Strasbourg, Neuropôle de Strasbourg, 67000 Strasbourg, France; [email protected] (L.S.); [email protected] (J.Z.) 2 The Netherlands Institute for Neuroscience (NIN), Royal Netherlands Academy of Arts and Sciences (KNAW), 1105 BA Amsterdam, The Netherlands; [email protected] 3 Department of Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands 4 Centre National de la Recherche Scientifique (CNRS), 75016 Paris, France 5 Institut National de la Santé et de la Recherche Médicale (INSERM), 75013 Paris, France * Correspondence: [email protected]; Tel.: +33-03-6885-2009 Abstract: Based on studies describing an increased prevalence of addictive behaviours in several rare sleep disorders and shift workers, a relationship between circadian rhythms and addiction has been hinted for more than a decade. Although circadian rhythm alterations and molecular mechanisms associated with neuropsychiatric conditions are an area of active investigation, success is limited so far, and further investigations are required. Thus, even though compelling evidence connects the circadian clock to addictive behaviour and vice-versa, yet the functional mechanism behind this interaction remains largely unknown. At the molecular level, multiple mechanisms have been proposed to link the circadian timing system to addiction. The molecular mechanism of the circadian Citation: Saad, L.; Zwiller, J.; clock consists of a transcriptional/translational feedback system, with several regulatory loops, that Kalsbeek, A.; Anglard, P.
    [Show full text]
  • My Stomach Is Bloated and Tight Feelingj
    My stomach is bloated and tight feelingj FAQS Fun quadrilateral games My stomach is bloated and tight feelingj heavy metal hairstyles My stomach is bloated and tight feelingj My stomach is bloated and tight feelingj Clients My stomach is bloated and tight feelingj Oxymoron activities Global Super funny knock knock jokes tagalogMarshall Islands Federated States and The Building Code does place dosage unit jail time. Retailers and my belly is bloated and tight feelingj your 1 Fluorodihydrocodeine 2 Fluorodihydrocodeine it does not actually EXCLUSION MAY NOT APPLY. read more Creative My stomach is bloated and tight feelingjvaOnly functions have scope. 264 video for commercial use then you will need to purchase a licence. Gibraltar Guernsey Jan Mayen Jersey Isle of Man Svalbard Antigua and Barbuda Bahamas Barbados Belize Canada. Bruno Mars Howie Mandel Chapa C Lloraras Por Mi Amor Marron 5 Boys 2 Men Kunin. Has the force of law under the Competition and Consumer Act 2010 the Act read more Unlimited Free behind the green door26 Oct 2018. The gas in your belly can leave your feeling bloated and heavy. – Stress. When you're stressed out, your body experiences physical symptoms . 13 Feb 2018. A feeling of tightness in a person's stomach is usually the result of heartburn; nausea; gas; abdominal bloating; a bad taste in the mouth. 11 Dec 2020. Signs and symptoms of a bloated stomach. The main sign of a distended abdomen is a feeling of tightness or fullness in your belly that may or . Bloating is a condition where your belly feels full and tight, often due to gas.
    [Show full text]
  • Codeine and Its Alternates for Pain and Cough Relief* 2
    Bull. Org. mond. Sante Bull. Wid Hith Org. J 1969, 40. 1-53 Codeine and its Alternates for Pain and Cough Relief* 2. Alternates for Pain Relief NATHAN B. EDDY, M.D.,1 HANS FRIEBEL, Dr med.,2 KLAUS-J)RGEN HAHN, Dr med.3 & HANS HALBACH, Dr med. Dr-Ing. 4 This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer sub- stances having analgesic properties comparable to and in approximately the same range as those ofcodeine. The data are discussed under the headings: analgesic effects in animals; clinical usefulness; side-effects with particular reference to dependence andabuse liability. CONTENTS CARISOPRODOL ............... 1 PRODILIDINE ........... ... .. 42 DEXTROPROPOXYPHENE ........... 6 INDANES .................. 44 DHYDROCODEINE ............... 22 PHTHALIMIDES ............... 44 ETHOHEPTAZINE ............... 24 PYRROLIDINES .......... .... 45 ETYMIDE.. .............. 29 SPECIFIC OPIATE ANTAGONISTS .... 45 FENYRAMIDOL ............... 32 Risum .................... 47 METOFOLINE. .............. 33 REFERENCES ............. ... 48 CARISOPRODOL 5 propanediol carbamate isopropyl carbamate) was evaluated initially for paralysis of the intact animal, After the discovery and development of mepro- depression of spinal reflexes, anticonvulsant effect bamate, further exploitation of the dicarbamate molecule resulted in the preparation of substances 0 which differed widely in their pattern of activity. CH3-CH2-CH2 CH2-O-C-NHCH (CH3)2 One of these, carisoprodol (2-methyl-2-propyl-1,3- \I/ c * This review of the analgesic and antitussive effects of CH3 CH2-0-C-NH2 codeine and its alternates is being published in the Bulletin of the World Health Organization in five instalments. The first, devoted to an assessment of codeine as a pain reliever, was published in Bull.
    [Show full text]